Single‐Batch Expression of an Experimental Recombinant Snakebite Antivenom Based on an Oligoclonal Mixture of Human Monoclonal Antibodies
Biotechnology Journal · 2024
DOI: 10.1002/biot.202400348 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biotechnology Journal, 2024. Verfasst von Anna C Adams und 6 weiteren Autor:innen. Beteiligte Einrichtung: Center for Biosustainability, Technical University of Denmark, Lyngby, Denmark. Hauptthemen laut MEDLINE: Antivenins, Antibodies, Monoclonal, Recombinant Proteins. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Wellcome Trust.
Abstract (Originalsprache)
Oligoclonal antibodies, which are carefully defined mixtures of monoclonal antibodies, are valuable for the treatment of complex diseases, such as infectionss and cancer. In addition to these areas of medicine, they could be utilized for the treatment of snakebite envenoming, where recombinantly produced monoclonal human antibodies could overcome many of the drawbacks accompanying traditional antivenoms. However, producing multiple individual batches of monoclonal antibodies in an industrial setting is associated with significant costs. Therefore, it is attractive to produce oligoclonal antibodies by mixing multiple antibody‐producing cell lines in a single batch to have only one upstream and downstream process. In this study, we selected four antibodies that target different toxins found in the venoms of various elapid snake species, such as mambas and cobras, and generated stable antibody‐producing cell lines. Upon co‐cultivation, we found the cell line ratios to be stable over 7 days. The purified oligoclonal antibody cocktail contained the anticipated antibody concentrations and bound to the target toxins as expected. These results thus provide a proof of concept for the strategy of mixing multiple cell lines in a single batch to manufacture tailored antivenoms recombinantly, which could be utilized for the treatment of snakebite envenoming and in other fields where oligoclonal antibody mixtures could find utility.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Biosustainability, Technical University of Denmark, Lyngby, Denmark.
- Department of Biotechnology and Biomedicine, Technical University of Denmark, Lyngby, Denmark.
- Australian Institute for Biotechnology and Nanotechnology, St Lucia, Australia.
ORCID-Profile: Anna C Adams, Lise M Grav, Shirin Ahmadi, Anne Ljungars, Andreas H Laustsen, Lars K Nielsen
Förderung
- Wellcome Trust
Zitieren
APA
Adams, A. C., Grav, L. M., Ahmadi, S., Holst Dahl, C., Ljungars, A., Laustsen, A. H., & Nielsen, L. K. (2024). Single‐Batch Expression of an Experimental Recombinant Snakebite Antivenom Based on an Oligoclonal Mixture of Human Monoclonal Antibodies. Biotechnology Journal. https://doi.org/10.1002/biot.202400348
Vancouver
Adams AC, Grav LM, Ahmadi S, Holst Dahl C, Ljungars A, Laustsen AH, et al. Single‐Batch Expression of an Experimental Recombinant Snakebite Antivenom Based on an Oligoclonal Mixture of Human Monoclonal Antibodies. Biotechnology Journal. 2024. doi:10.1002/biot.202400348
BibTeX
@article{Adams2024,
author = {Adams, Anna C and Grav, Lise M and Ahmadi, Shirin and Holst Dahl, Camilla and Ljungars, Anne and Laustsen, Andreas H and Nielsen, Lars K},
title = {Single‐Batch Expression of an Experimental Recombinant Snakebite Antivenom Based on an Oligoclonal Mixture of Human Monoclonal Antibodies},
journal = {Biotechnology Journal},
year = {2024},
doi = {10.1002/biot.202400348}
}
EUVIMED